IN8bioINAB
About: IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Employees: 39
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
1.39% less ownership
Funds ownership: 17.55% [Q2] → 16.16% (-1.39%) [Q3]
8% less funds holding
Funds holding: 26 [Q2] → 24 (-2) [Q3]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
70% less capital invested
Capital invested by funds: $6.77M [Q2] → $2.04M (-$4.73M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 26% 1-year accuracy 37 / 144 met price target | 2,424%upside $8 | Buy Maintained | 13 Nov 2024 |
